Recent

% | $
Quotes you view appear here for quick access.

Celgene Corporation Message Board

  • padakri padakri Dec 28, 2005 9:31 PM Flag

    WSJ talks about estimate changes

    Estimates are being revised even at Morgan Stanley, I am sure the estimates and the price targets will be revised too. :-)

    "On a monthly basis, Revlimid is priced at about the same as Velcade, according to Sapna Srivastava, biotechnology analyst at Morgan Stanley who covers the company. Dr. Srivastava said Celgene priced Revlimid much higher than she had expected and so she was predicting eventual sales in excess of the $1 billion she had previously estimated."

 
CELG
123.04+3.81(+3.20%)4:00 PMEDT